Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin
1996

Reducing Kidney Toxicity in Cancer Treatment

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): E Otsuji, T Yamaguchi, H Matsumura, K Yamamoto, H Tsuruta, Y Yata, H Nishi, K Okamoto, K Kitamura, T Takahashi

Primary Institution: Kyoto Prefectural University of Medicine

Hypothesis

Can the administration of avidin reduce the kidney accumulation of biotinylated chimeric monoclonal antibody Fab fragments conjugated with neocarzinostatin?

Conclusion

The administration of avidin significantly decreases the accumulation of biotinylated chA7Fab and biotinylated chA7Fab-NCS in the kidneys without affecting tumor accumulation.

Supporting Evidence

  • The accumulation of biotinylated chA7Fab in the blood and kidneys decreased significantly after the injection of avidin.
  • Significant differences in kidney accumulation were observed at 1 and 6 hours after injection.
  • The administration of avidin did not affect the tumor accumulation of biotinylated chA7Fab-NCS.

Takeaway

This study found that giving avidin after a special cancer treatment can help protect the kidneys while still allowing the treatment to work on tumors.

Methodology

Nude mice with pancreatic cancer were injected with biotinylated chA7Fab and then given avidin to observe changes in accumulation in blood and kidneys.

Potential Biases

Potential bias in the selection of animal models and the interpretation of results.

Limitations

The study was conducted on a small sample size of mice, and results may not directly translate to human patients.

Participant Demographics

Nude mice bearing human pancreatic carcinoma xenografts.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication